HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

GSK372475

triple reuptake inhibitor against serotonin, norepinephrine, and dopamine transporters

Also Known As:

NS2359

Networked: 2 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Aza Compounds: 3
  - Azabicyclo Compounds
    - Tropanes: 1
      - GSK372475: 2
Heterocyclic Compounds: 198
- Alkaloids: 5398
  - Tropanes: 1
    - GSK372475: 2
- Bridged-Ring Heterocyclic Compounds
  - Tropanes: 1
    - GSK372475: 2
  - Heterocyclic Bridged Bicyclo Compounds
    - Azabicyclo Compounds
      - Tropanes: 1
        GSK372475: 2

Experts

1.	Graff, Ole: 2 articles (05/2012 - 06/2008)
2.	Alexander, Robert: 1 article (05/2012)
3.	Archer, Graeme: 1 article (05/2012)
4.	Evoniuk, Gary: 1 article (05/2012)
5.	Krishnan, K Ranga: 1 article (05/2012)
6.	Lavergne, Agnes: 1 article (05/2012)
7.	Learned, Susan: 1 article (05/2012)
8.	Moate, Rachel: 1 article (05/2012)
9.	Modell, Jack G: 1 article (05/2012)
10.	Ratti, Emiliangelo: 1 article (05/2012)

Related Diseases

1.	Major Depressive Disorder (Major Depressive Disorders) 05/01/2012 - "Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trials." 05/01/2012 - "Two randomized, placebo- and active-controlled, double-blind studies examined the efficacy and safety of GSK372475 in outpatients (aged 18-64 years) with a diagnosis of major depressive episode associated with major depressive disorder (MDD). "
2.	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 06/13/2008 - "The aim of the study was to investigate the efficacy, safety and cognitive function of NS2359 in adults with a DSM IV diagnosis of ADHD. " 06/13/2008 - "No overall effect of NS2359 was found on overall symptoms of ADHD. " 06/13/2008 - "There was no significant difference between NS2359 (n = 63) versus placebo (n = 63) on the primary outcome measure reduction in investigator rated ADHD-RS total score (7.8 versus 6.4; p < 0.45). "
3.	Tachycardia (Tachyarrhythmias) 05/01/2012 - "AEs were more frequent for GSK372475 versus placebo for sleep, anxiety-related, gastrointestinal, and tachycardia events. "
4.	Nausea 05/01/2012 - "The most common adverse effects (AEs) with GSK372475 were dry mouth, headache, insomnia, and nausea. "
5.	Sleep Initiation and Maintenance Disorders (Insomnia) 05/01/2012 - "The most common adverse effects (AEs) with GSK372475 were dry mouth, headache, insomnia, and nausea. "